Abstract
Somatic mutations in cancer can be translated into peptides, termed neoantigens, which can be recognized by the immune system as "foreign" epitopes. Two recent studies in Nature (Sahin et al., 2017; Ott et al., 2017) examine the effects of neoantigen vaccines on patients with stage III or IV melanoma and demonstrate immunogenicity and intriguing clinical safety and efficacy data in phase I studies.
Copyright © 2017 Elsevier Inc. All rights reserved.
MeSH terms
-
Animals
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology*
-
Autoantigens / genetics
-
Cancer Vaccines / immunology*
-
Clinical Trials, Phase I as Topic
-
Humans
-
Immunotherapy / methods*
-
Melanoma / immunology
-
Melanoma / pathology
-
Melanoma / therapy*
-
Mutation / genetics
-
Neoplasm Metastasis
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
-
Skin Neoplasms / therapy*
-
Vaccines, Subunit
Substances
-
Antigens, Neoplasm
-
Autoantigens
-
Cancer Vaccines
-
Vaccines, Subunit